In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Audentes Therapeutics (BOLD), with a price target of $45. The company’s shares closed yesterday at $27.77.
Yang noted:
“We believe this event will be an important catalyst for the shares. From a safety standpoint, management indicated that AT132 continues to be well tolerated, including at the higher dose.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 18.2% and a 50.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.
Audentes Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $37.67, representing a 35.6% upside. In a report issued on February 24, Chardan Capital also upgraded the stock to Buy with a $40 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $46.18 and a one-year low of $17.95. Currently, Audentes Therapeutics has an average volume of 521.6K.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BOLD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.
